Tetrofosmin label

Tetrofosmin

Tetrofosmin Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

Tetrofosmin is a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function.

PHYSICAL HALF-LIFE & TARGET ORGANS

The physical half-life of technetium, Tc99m, is 6 hours and has a principal radiation emission of gamma photons with a mean energy of 140 KeV.

Estimated Absorbed Radiation Dose (Technetium Tc99m Tetrofosmin Injection)
Absorbed radiation dose
Exercise Rest
Target organ rad/mCi µGy/MBq rad/mCi µGy/MBq
Gall bladder wall 0.123 33.2 0.180 48.6
Upper large intestine 0.075 20.1 0.113 30.4
Bladder wall 0.058 15.6 0.071 19.3
Lower large intestine 0.057 15.3 0.082 22.2
Small intestine 0.045 12.1 0.063 17.0
Kidney 0.039 10.4 0.046 12.5
Salivary glands 0.030 8.04 0.043 11.6
Ovaries 0.029 7.88 0.035 9.55
Uterus 0.027 7.34 0.031 8.36
Bone surface 0.023 6.23 0.021 5.58
Pancreas 0.019 5.00 0.018 4.98
Stomach 0.017 4.60 0.017 4.63
Thyroid 0.016 4.34 0.022 5.83
Adrenals 0.016 4.32 0.015 4.11
Heart wall 0.015 4.14 0.015 3.93
Red marrow 0.015 4.14 0.015 3.97
Spleen 0.015 4.12 0.014 3.82
Muscle 0.013 3.52 0.012 3.32
Testes 0.013 3.41 0.011 3.05
Liver 0.012 3.22 0.015 4.15
Thymus 0.012 3.11 0.009 2.54
Brain 0.010 2.72 0.008 2.15
Lungs 0.008 2.27 0.008 2.08
Skin 0.008 2.22 0.007 1.91
Breasts 0.008 2.22 0.007 1.83

Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No.1 (rev),Society of Nuclear Medicine, 1976).

Effective dose equivalents (EDE) were calculated in accordance with ICRP 53 (Ann. ICRP 18 (1-4),1988) and gave values of 8.61 × 10-3 mSV/MBq and 1.12 × 10-2 mSV/MBq after exercise and rest, respectively.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

AnazaoHealth’s compounded Tetrofosmin vial is a sterile, non-pyrogenic preparation that consists of a lyophilized mixture of 0.35 mg of Tetrofosmin, 1.5 mg of D-Gluconate, 0.03 mg of Stannous Chloride Dihydrate, 0.48 mg of Disodium Sulphosalicylate, and 2.7 mg of Sodium Hydrogen Carbonate and is maintained under an inert nitrogen atmosphere. It contains no antimicrobrial preservative.

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Tetrofosmin Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Tetrofosmin Manufacturers

  • Anazaohealth Corporation
    Tetrofosmin | Anazaohealth Corporation
    No Recall

    Tetrofosmin | Anazaohealth Corporation

    Tetrofosmin | Anazaohealth Corporation

    Depending on the protocol for rest/stress imaging, doses of 10 to 30 mCi (370 to 1110 MBq) are given intravenously

    PREPARATION

    Snap off the plastic lid and place in appropriate lead shielding. Wipe the septum with 70% isopropyl alcohol and allow it to dry. Using a 10 mL syringe, dilute up to 360 mCi of Tc99m with saline and add to vial. The total volume should be between 6 mL -12 mL and the Tc99m concentration should not exceed 30 mCi/mL (360 mCi/12 mL). After adding the Tc99m, insert a 0.22 µm filtered vent needle and, using a separate syringe, withdraw 3 mL of gas from the vial, allowing sterile filtered air into the vial. Remove vent needle and syringe. Mix gently and invert several times for 10 seconds. Let stand for 15 minutes at room temperature as the complexes form. Inspect vial through a lead glass shield for particulate matter. Do not use if the solution is not clear. Store at 2°- 8°C (36°- 46°F) and use within 12 hours after mixing. Radiochemical purity should be at least 90% prior to administration QC info: Solvent – Ethyl Acetate, Strip – Whatman CHR% Tag = top counts/total counts X 100%

    STORAGE

    The preparation should be stored in the refrigerator at 2- 8(C (36 - 46(F) and protected from light.

  • Anazaohealth Corporation
    Tetrofosmin | Anazaohealth Corporation
    No Recall

    Tetrofosmin | Anazaohealth Corporation

    Tetrofosmin | Anazaohealth Corporation

    Depending on the protocol for rest/stress imaging, doses of 10 to 30 mCi (370 to 1110 MBq) are given intravenously

    PREPARATION

    Snap off the plastic lid and place in appropriate lead shielding. Wipe the septum with 70% isopropyl alcohol and allow it to dry. Using a 10 mL syringe, dilute up to 360 mCi of Tc99m with saline and add to vial. The total volume should be between 6 mL -12 mL and the Tc99m concentration should not exceed 30 mCi/mL (360 mCi/12 mL). After adding the Tc99m, insert a 0.22 µm filtered vent needle and, using a separate syringe, withdraw 3 mL of gas from the vial, allowing sterile filtered air into the vial. Remove vent needle and syringe. Mix gently and invert several times for 10 seconds. Let stand for 15 minutes at room temperature as the complexes form. Inspect vial through a lead glass shield for particulate matter. Do not use if the solution is not clear. Store at 2°- 8°C (36°- 46°F) and use within 12 hours after mixing. Radiochemical purity should be at least 90% prior to administration QC info: Solvent – Ethyl Acetate, Strip – Whatman CHR% Tag = top counts/total counts X 100%

    STORAGE

    The preparation should be stored in the refrigerator at 2- 8(C (36 - 46(F) and protected from light.

Login To Your Free Account